Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Coeptis Receives Shareholder Approval Towards Z Squared Merger

WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced that its shareholders have voted to approve the previously announced merger with Z Squared Inc. The transaction was approved on January 30, 2026, by Coeptis' shareholders.

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~ ~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”).